High dose aflibercept switch for wet AMD patients
Part of Eyes & vision clinical trials.
This trial tests switching to a higher dose of aflibercept for people with wet age-related macular degeneration (AMD) who have already had several standard doses. It aims to see if a higher dose works better at keeping vision stable and reducing treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have wet age-related macular degeneration (a condition causing vision loss from abnormal blood vessels in the eye).
- You have already received at least 3 starter injections of aflibercept (a medicine) plus 2 maintenance injections.
- You do not have other eye conditions like certain types of macular disease, scars, or atrophy in the central vision area.
- You have not had laser treatment for eye problems before.
- You are not participating in another study or using a different anti-VEGF medicine in your other eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational eye injection called AL-001 for people with wet age-related macular degeneration (AMD) that has responded to previous anti-VEGF treatment. The goal is to see if it improves vision and is safe.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a higher dose of aflibercept given on a flexible schedule for people who have not yet been treated for wet age-related macular degeneration (nAMD). It aims to see if this approach is safe and effective at improving vision.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This study tests a higher dose of the medicine aflibercept (brand name Eylea) in people who have already had at least three eye injections for wet age-related macular degeneration or diabetic macular edema. The goal is to see how well this stronger dose works in real-life conditions and how long its effects last.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
Hear when a new Wet Age-related Macular Degeneration (wAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.